No abstract

No abstract

Feruloyl esterases (FAEs) of a strain of Aspergillus niger (CFR 1105) grown in solid state (ssf) and submerged fermentations (smf) using wheat bran both as carbon source and inducer of the enzyme were studied. The feruloyl esterase activity was maximum after 4 days in solid state as well as in submerged fermentations (32.5 and 31.5 U/g dry weight of wheat bran respectively) and the enzyme titers were comparable. The specific activity was maximum on day 2 in ssf (12.8 U/mg protein) and it decreased thereafter, whereas specific activity was maximum on day 3 (11.7 U/mg protein) in smf and it remained constant up to 5 days. Two isoenzymes of feruloyl esterases were isolated and purified to homogeneity by conventional protein purification methods from the day 5 culture filtrate of A. niger grown in smf. On a DEAEcellulose column, two enzyme activity peaks designated as FAE-1 and FAE-2 were eluted with 0.3 and 0.35 M NaCl, respectively. They were monomeric glycoproteins with approximate molecular weights of 50 kDa (FAE-1) and 55 kDa (FAE-2), respectively. FAE-1 showed a temperature optimum of 40°C whereas FAE-2 showed a wider temperature optimum of 40-50°C. FAE-1 and FAE-2 exhibited pH optima of 9 and 6, respectively, and both were stable over a pH range of 6-9. The ability of the enzyme to be active in alkaline pH may be advantageous in biotechnological applications.

In 2019, * 463 million people globally had diabetes mellitus (DM), with China (25.1%), India (16.6%), and the United States (6.69%) representing nearly 50% of that total. The primary objectives of this exploratory study were to assess the safety and potential efficacy of Nigella sativa and fenugreek seed supplemented chapatis in overweight (OW) and type 2 DM subjects. Forty subjects (15/OW; 9/DM; 16/DM/OW) consumed two chapatis twice a day 6 days/week for a daily dose of 5.45 g of an N. sativa/fenugreek combination over 12 weeks with no changes in lifestyle or medications. Anthropometric, glycemic, and vascular variables were recorded at baseline and after 6 and 12 weeks. Glycated hemoglobin (HbA1c), plasma lipids, and complete metabolic profile were measured at baseline and termination. Compliance, estimated during twice-daily individual delivery of precooked chapatis, was 100%, with no significant adverse effects. At termination, body weights, body mass index, waist and hip circumferences, index of central obesity, HbA1c, fasting blood glucose, 2-h postprandial blood glucose, estimated average glucose over 12 weeks, total cholesterol (TC), non-high density lipoprotein (HDL) cholesterol, very low density lipoprotein (VLDL), and triglycerides (TG) were decreased (P < .05) over all subjects. Subjects with HbA1c ‡7.0 exhibited greater improvements in all glycemic variables than HbA1c <7.0 subjects. In addition, the decrease in HbA1c was positively correlated with decreases in (1) hepatic enzymes alkaline phosphatase (r = 0.301, P = .0067) and aspartate transaminase (r = 0.277, P = .0129), (2) systolic blood pressure (r = 0.388, P = .0004), and (3) number of diagnostic metabolic syndrome criteria exhibited per subject (r = 0.391, P = .0005), cardiovascular risk score (CRS) (r = 0.281, P = .0115), and hepatic steatosis index (HSI) (r = 0.223, P = .0467). Atherogenic and diabetogenic indexes TC/HDL, low density lipoprotein/HDL, VLDL/HDL, and TG/HDL were all decreased (P < .05). Among all subjects, improvement (P < .05) was seen in CRS (-10.7%), fatty liver index (-19.8%), lipid accumulation product (-13.8%), and HSI (-7.53%). N. sativa/fenugreek supplemented chapatis present a safe and seamless dietary modification to address cardiometabolic risk.

No abstract